Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Alpha-Glycosyl Isoquercetin (AGIQ) is a glycosylated form of isoquercetin, a derivative of the flavonoid quercetin. Its use in supporting or treating diabetic retinopathy is based on emerging, but still limited, scientific evidence. The rationale for its use stems from its antioxidant, anti-inflammatory, and potential vascular-protective effects. Preclinical studies (in vitro and in animal models) suggest that AGIQ and related flavonoids can reduce oxidative stress, inhibit inflammatory pathways, and protect retinal cells from hyperglycemia-induced damage—all factors involved in the pathogenesis of diabetic retinopathy.

AGIQ is more bioavailable than quercetin, allowing for potentially greater efficacy in vivo. Some rodent studies have shown that AGIQ supplementation reduced retinal oxidative damage and improved microvascular integrity in diabetic models. However, direct clinical trials in humans with diabetic retinopathy are lacking. Most available human data focus on quercetin or general polyphenol intake, rather than AGIQ specifically, and are preliminary in nature.

In summary, while there is a plausible scientific rationale and some promising preclinical evidence, there is insufficient high-quality clinical research in humans to strongly support the use of Alpha-Glycosyl Isoquercetin for diabetic retinopathy at this time. Thus, the evidence rating is 2 out of 5, reflecting early-stage scientific support that requires further validation.

More about Alpha-Glycosyl Isoquercetin
More about Diabetic Retinopathy

Other ingredients used for Diabetic Retinopathy

Other health conditions supported by Alpha-Glycosyl Isoquercetin

Products containing Alpha-Glycosyl Isoquercetin